Evidence map›Paper›PMID 42163181›Full record

ArticleBMC ophthalmology2026

Outcome and factors affecting prognosis in treat and extend treatment for neovascular age-related macular degeneration-a real world study.

Fatma Sema Akkan Aydogmus, Tugba Gursoy, Ozdemir Ozdemir, Ozgul Ucar Elalmis, Defne Kalayci

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fatma Sema Akkan AydogmusDepartment of Ophthalmology, Retina Unit, University of Health Sciences Ankara Bilkent City Hospital, Ankara, Turkey.ORCID http://orcid.org/0000-0001-7088-7303
Tugba GursoyDepartment of Cardiology, Ankara Etlik City Hospital, Ankara, Turkey.
Ozdemir OzdemirDepartment of Ophthalmology, Retina Unit, University of Health Sciences Ankara Bilkent City Hospital, Ankara, Turkey.
Ozgul Ucar ElalmisDepartment of Cardiology, University of Health Sciences Ankara Bilkent City Hospital, Ankara, Turkey.
Defne KalayciDepartment of Ophthalmology, Retina Unit, University of Health Sciences Ankara Bilkent City Hospital, Ankara, Turkey. dakalayci@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate the outcome of treat and extend (T&E) for neovascular age related macular degeneration (nAMD) at 12, 18 and 24 months and the impact of clinical characteristics on treatment success defined as extension of treatment interval to ≥12 weeks and functional improvement or stability.

methodsVisual and anatomical outcomes evaluated by optical coherence tomography (OCT) and extension of treatment interval to ≥12 weeks were analyzed retrospectively. Clinical factors effective on extension of the treatment interval and visual outcome were evaluated.

resultsThere were 138 eyes with at least 18 months of follow-up. Patients exhibited a significant improvement in visual acuity and reduction in central subfield thickness (CST), subretinal fluid (SRF), intraretinal fluid (IRF) and pigment epithelial detachment (PED) at both the 12

conclusionPresence of IRF and a visual acuity of ≤20/100 at baseline were found to be negative predictors for visual prognosis, while large PED was a negative predictive factor for less frequent treatment, but it did not affect visual outcome. Treatment interval should be extended cautiously in patients with baseline intraretinal fluid and visual acuity of ≤20/100 in order to balance decreasing the burden of treatment by longer treatment intervals with improvement of visual gain.

Indexed as

Angiogenesis InhibitorsRanibizumabVisual AcuityWet Macular DegenerationAgedAged, 80 and overFemaleFluorescein AngiographyFollow-Up StudiesHumansIntravitreal InjectionsMalePrognosisReceptors, Vascular Endothelial Growth FactorRetrospective StudiesTomography, Optical CoherenceAngiogenesis InhibitorsRanibizumabReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AAnti-vascular endothelial growth factorNeovascular age related macular degenerationPigment epithelial detachmentTreat and extend

Identifiers

PMID42163181
PMCPMC13366986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.